Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial performance, with significant growth in hospital volume, collaboration revenue, and a solid cash position. The Q&A section reveals management's strategic focus on improving YUPELRI's channel mix and addressing payer perspectives for ampreloxetine. Despite some uncertainties in the timeline and pricing, overall sentiment remains positive due to strong revenue growth and financial health. The lack of market cap data suggests a moderate reaction, leading to a 'Positive' prediction for stock price movement.
Key Financial Performance
YUPELRI Net Sales Net sales for the quarter reached approximately $66 million, a 22% increase year-over-year. This growth was driven by solid demand growth (up 4% versus Q2 of 2024 and 5% sequentially from Q1 of 2025), continued net price improvement supported by pricing discipline and a favorable channel mix, and a one-time favorable adjustment to net pricing.
YUPELRI Hospital Volume Hospital volume increased 31% versus Q2 of 2024. This was attributed to sustained success in securing formulary wins and implementing therapeutic interchange protocols.
TRELEGY Milestones GSK reported $1.1 billion in sales for Q2, an 8% increase year-over-year. This performance strengthens the likelihood of achieving $150 million in milestones over the next 18 months, including a $50 million milestone for exceeding $3.4 billion in annual sales in 2025 and an additional $100 million milestone in 2026 for $3.5 billion in annual sales.
Collaboration Revenue Collaboration revenue grew 31% year-over-year, driven by continued YUPELRI net sales growth and improved brand-level profit margins. Even excluding the one-time pricing benefit, collaboration revenue would have been over $17 million.
License Revenue A one-time $7.5 million milestone was recognized following YUPELRI's regulatory approval in China.
Cash Position Theravance ended the quarter with approximately $340 million in cash and no debt. Cash burn for the quarter was approximately $3 million, excluding large one-time items.
Non-GAAP Losses Non-GAAP losses improved to $4.2 million compared to $6.3 million in the prior year, excluding one-time items. This improvement reflects strong cash management and cost discipline.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
YUPELRI: Net sales for the quarter reached approximately $66 million, driven by continued demand growth and favorable net pricing. YUPELRI received approval in China, triggering a $7.5 million milestone payment.
Ampreloxetine: Phase III CYPRESS trial is progressing well, with enrollment in the open-label portion expected to complete in the next couple of weeks. The trial aims to address neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
China market expansion: YUPELRI received approval by China's National Medical Products Administration, triggering a $7.5 million milestone payment. Viatris will lead launch and commercialization efforts in China.
TRELEGY royalty sale: Completed the $225 million sale of remaining royalty interest in TRELEGY to GSK, strengthening the balance sheet. Potential to receive $150 million in milestones from Royalty Pharma over the next 18 months.
Financial performance: Ended the quarter with approximately $340 million in cash and no debt. Operations remain near cash neutral.
Strategic review outcomes: The sale of TRELEGY royalty interest and focus on unlocking shareholder value through disciplined capital management and potential milestone payments.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Market Conditions: Potential risks related to achieving the $250 million calendar year sales threshold for YUPELRI to trigger a $25 million milestone payment, which depends on sustained demand growth and pricing discipline.
Regulatory Hurdles: Uncertainty around the commercialization plan and launch timing for YUPELRI in China, as Viatris is still finalizing the plan.
Strategic Execution Risks: Dependence on the successful completion and positive results of the CYPRESS Phase III study for ampreloxetine, which is critical for the company's future growth and strategic objectives.
Economic Uncertainties: Potential tax liabilities related to the TRELEGY royalty sale, with $27 million in taxes expected in the second half of the year.
Supply Chain Disruptions: No explicit mention of supply chain risks, but the reliance on Viatris for YUPELRI's commercialization in China could pose indirect risks if supply chain issues arise.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
YUPELRI Sales and Milestones: Theravance expects to achieve the $250 million calendar year sales threshold for YUPELRI, triggering a $25 million milestone payment. The product is projected to deliver long-term sustainable value with patent protection into 2039.
Ampreloxetine Development and Market Opportunity: The CYPRESS Phase III study for ampreloxetine is nearing completion of enrollment, with top-line data expected approximately six months after. If successful, the drug could redefine the standard of care for neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA). The company estimates an addressable U.S. market of approximately 40,000 patients and is preparing for expedited regulatory submission and potential priority review.
TRELEGY Milestones: Theravance anticipates achieving $150 million in milestones over the next 18 months, tied to TRELEGY's sales performance. This includes a $50 million milestone in 2025 and an additional $100 million milestone in 2026.
Financial Guidance: The company reaffirmed its 2025 financial guidance, expecting improved non-GAAP losses and cash burn in the second half of the year compared to 2024. It also highlighted a strong financial position with $340 million in cash and no debt.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Program: No specific mention of a dividend program was made during the call.
Share Buyback Program: No specific mention of a share buyback program was made during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is attributed to the better pull-through for YUPELRI this quarter?
A:The better pull-through is attributed to the move of volume to specialty pharmacy, which improves pricing, persistency, and patient support. Fulfillment and persistency are much greater in this channel.
Q:What is the realistic optimal channel mix for YUPELRI, and how long might it take to achieve it?
A:Management emphasized the importance of keeping an open network to meet individual patient needs and focused on educating clinicians. They did not provide a specific timeline or details on achieving an optimal channel mix.
Q:What services do specialty pharmacies provide that improve persistence for YUPELRI?
A:Specialty pharmacies provide reminders on refills, dedicated outreach, and follow-up personnel, which improve persistence compared to conventional retail pharmacies.
Q:What is the outlook for YUPELRI's near-term growth in China and the longer-term market opportunity?
A:Management deferred comments on the market plan and full launch plan for YUPELRI in China to Viatris, providing no specific details.
Q:How is U.S. versus ex-U.S. enrollment trending for the CYPRESS study, and will baseline characteristics be disclosed?
A:The U.S. versus ex-U.S. enrollment split is expected to be similar to the previous 170 study. Baseline characteristics will not be disclosed until the top-line readout.
Q:What are the thoughts on pricing ampreloxetine, and is Northera a good benchmark?
A:Management mentioned that it is too early to determine a specific price. They referenced an analysis of rare neuro drug launches with an average price of $380,000 per year and Northera's annual cost of $280,000 as benchmarks.
Q:Are there differences in reimbursement and payer perspectives between the U.S. and ex-U.S. for ampreloxetine?
A:Management focused on the U.S. market, emphasizing the importance of educating payers about the disease and unmet needs. They highlighted the significance of data durability and safety profile for payer acceptance.
Q:What is the expected pace of SG&A increases associated with ampreloxetine sales build-out?
A:SG&A is expected to remain stable through the year until the CYPRESS data readout. Post-readout, there will be incremental spend for a targeted launch, but the magnitude will not be huge.
Q:Should we expect continued operating leverage in coming quarters with collaboration revenue growing higher than YUPELRI sales?
A:Management does not expect a significant gap between collaboration revenue and net sales growth going forward. However, profit margins are expected to increase as net sales grow.
Q:How does the longer duration primary endpoint in the CYPRESS study impact results compared to previous studies?
A:The longer duration primary endpoint focuses on durability of effect, which is a key differentiator. Management expects patients on ampreloxetine to maintain stability in benefits, while those taken off the drug would worsen.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the optimal channel mix timeline for YUPELRI, the market plan for YUPELRI in China, and the exact pricing for ampreloxetine. They also deferred baseline characteristic disclosures for the CYPRESS study until the top-line readout.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
LLC Research
MSA subgroup
Medical
REDWOOD study
Reed
Research Division
Senior VP
Slide
Study
Theravance
YUPELRI approval
activity
ampreloxetine
atrophy MSA
calendar sale
committee
community outpatient
cost discipline
couple week
criterion study
design
development program
differentiator
engagement
hypotension nOH
mechanism
milestone payment
onetime
phase
precision
pricing
readiness
readout
sale threshold
site
stage
tax
withdrawal
worsening
TBPH Transcript
Theravance Biopharma, Inc. (TBPH) Q3 2025 Earnings Call Transcript
Positive11-11
The earnings call highlighted strong financial performance with YUPELRI's sales growth and a robust cash position. The company's strategic focus on the CYPRESS study and potential ampreloxetine launch is promising, despite some regulatory risks. The Q&A revealed confidence in study design and operational execution, with analysts showing interest in future capital returns and pipeline evaluations. Overall, the positive financial metrics, strategic milestones, and optimistic outlook outweigh the risks, suggesting a positive stock price movement.
Theravance Biopharma, Inc. (TBPH) Q2 2025 Earnings Call Transcript
Positive8-12
The earnings call summary indicates strong financial performance, with significant growth in hospital volume, collaboration revenue, and a solid cash position. The Q&A section reveals management's strategic focus on improving YUPELRI's channel mix and addressing payer perspectives for ampreloxetine. Despite some uncertainties in the timeline and pricing, overall sentiment remains positive due to strong revenue growth and financial health. The lack of market cap data suggests a moderate reaction, leading to a 'Positive' prediction for stock price movement.
Theravance Biopharma at Jones Conference: Strategic Growth and Future Prospects
Neutral4-11
Theravance Biopharma, Inc. (TBPH) Q4 2024 Earnings Call Transcript
Unknown2-26
The earnings call presents a mixed picture: strong YUPELRI sales growth and potential milestone payments are positive, but financial risks and supply chain challenges could dampen enthusiasm. The Q&A section reveals some uncertainty about hospital performance and regulatory timelines, which tempers optimism. Despite the company's commitment to shareholder returns, the lack of clear guidance on certain issues and typical seasonality concerns suggest a cautious market reaction, leading to a neutral sentiment.
TBPH Slides
TBPH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
